← Back to Search

Nucleoside Analog

ASTX727 for Leukemia

Phase 2
Waitlist Available
Research Sponsored by Taiho Oncology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must have a confirmed diagnosis of- i. MDS including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, CMML), and participants with MDS International Prognostic Scoring System (IPSS) int-1, -2, or high-risk MD. ii. AML, as diagnosed according to the 2016 World Health Organization (WHO) guidelines on acute leukemia, of any subtype except M3 (acute promyelocytic leukemia), who are not candidates for intensive chemotherapy, including participants receiving hypomethylating agent (HMA) treatment, who have a confirmed diagnosis and a prior confirmatory bone marrow report. Participants who are currently receiving HMA treatment must complete the ongoing (at the time of Screening) treatment cycle before enrolling in this study; timing of start of treatment cycle with ASTX727 is at the principal investigator's discretion.
Adequate organ function defined as follows: Hepatic: Total bilirubin ≤1.5 × upper limit of normal (ULN); aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT) ≤5 × ULN. Renal: Calculated creatinine clearance ≥60 mL/min.
Must not have
Known history of human immunodeficiency virus or known seropositive for hepatitis C virus or hepatitis B virus.
Participants with known or suspected hypersensitivity to decitabine, cedazuridine, or any of the excipients in the ASTX727 tablets.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from day 1 up to day 28 in cycle 1 (up to 28 days)
Awards & highlights
No Placebo-Only Group

Summary

This trial is an extension of a previous study that found benefits from ASTX727 treatment. The purpose of the Food Effect Substudy is to study the effects of food on the drug's safety and how it is absorbed by the body.

Who is the study for?
This trial is for people who have certain types of leukemia or preleukemia and were previously benefiting from ASTX727 in an Astex-sponsored study. They must understand the study, not be pregnant or breastfeeding, use effective birth control, have a performance status of 0 to 2 (which measures how the disease affects daily living abilities), and adequate liver and kidney function.
What is being tested?
The trial continues treatment with ASTX727 for those who benefited from it before. It also studies how food affects the drug's absorption and safety by comparing its effects when taken with different meals versus no meal at all.
What are the potential side effects?
While specific side effects are not listed here, participants will be monitored for any adverse reactions related to ASTX727 which could include typical chemotherapy-related issues such as digestive problems, blood disorders, fatigue, or potential organ dysfunction.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a specific type of blood cancer and cannot undergo intensive chemotherapy.
Select...
My liver and kidney functions are within the required range.
Select...
I can take care of myself and am up and about more than half of my waking hours.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of HIV or tested positive for hepatitis B or C.
Select...
I am not allergic to decitabine, cedazuridine, or any ingredients in ASTX727 tablets.
Select...
I have an active stomach or upper small intestine ulcer that's not under control.
Select...
I have had stomach surgery that affects how my stomach moves or absorbs food.
Select...
I have acute promyelocytic leukemia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day 1 up to day 28 in cycle 1 (up to 28 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from day 1 up to day 28 in cycle 1 (up to 28 days) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Main Extension Study: Safety: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Secondary study objectives
Food Effect Substudy: Percentage of Participants with Clinically Significant Abnormal Laboratory Values
Therapeutic procedure

Side effects data

From 2023 Phase 3 trial • 227 Patients • NCT03306264
69%
Thrombocytopenia
61%
Neutropenia
55%
Anaemia
52%
Fatigue
49%
Constipation
48%
Nausea
42%
Diarrhoea
38%
Headache
35%
Dyspnoea
33%
Decreased Appetite
32%
Dizziness
31%
Cough
28%
Leukopenia
28%
Oedema Peripheral
25%
Arthralgia
25%
Febrile neutropenia
22%
Asthenia
21%
Pyrexia
21%
Hypokalaemia
20%
Oropharyngeal Pain
20%
Vomiting
20%
Back Pain
18%
Contusion
18%
Stomatitis
16%
Myalgia
15%
Abdominal Pain
15%
Alanine Aminotransferase Increased
15%
Insomnia
14%
Pain In Extremity
13%
Blood Creatinine Increased
13%
Rash Maculo-Papular
13%
Pneumonia
12%
Fall
12%
Nasal Congestion
12%
Hypotension
12%
Epistaxis
12%
Rash
12%
Upper Respiratory Tract Infection
12%
Urinary Tract Infection
11%
Aspartate Aminotransferase Increased
11%
Hypocalcaemia
11%
Hyperglycaemia
10%
Chills
10%
Muscle Spasms
10%
Alopecia
9%
Hyponatraemia
9%
Petechiae
8%
Sepsis
8%
Depression
8%
Cellulitis
8%
Blood Alkaline Phosphatase Increased
8%
Weight Decreased
8%
Bone Pain
8%
Nasopharyngitis
8%
Blood Bilirubin Increased
8%
Haematuria
8%
Anxiety
8%
Hypertension
7%
Hypoalbuminaemia
7%
Pruritus
7%
Toothache
7%
Non-Cardiac Chest Pain
7%
Hypomagnesaemia
7%
Haemorrhoids
6%
Dyspepsia
6%
Neck Pain
6%
Lymphopenia
6%
Pain
6%
Skin Lesion
6%
Musculoskeletal Pain
5%
Conjunctival Haemorrhage
5%
Pollakiuria
5%
Peripheral Swelling
5%
Dehydration
5%
Rhinorrhoea
5%
Rhinitis Allergic
5%
Night Sweats
5%
Febrile Neutropenia
5%
Dyspnoea Exertional
5%
Procedural Pain
2%
Proctitis
2%
Myocardial infarction
2%
Upper respiratory tract infection
2%
Gastrointestinal haemorrhage
2%
Embolism
2%
Colitis
2%
Diverticulitis
2%
Syncope
2%
Pneumothorax
2%
Influenza
1%
Respiratory failure
1%
Chronic obstructive pulmonary disease
1%
Rib fracture
1%
Thrombotic thrombocytopenic purpura
1%
Gingival bleeding
1%
Rectal haemorrhage
1%
Pharyngitis
1%
Influenza A virus test positive
1%
Pancreatic carcinoma metastatic
1%
Refractory cytopenia with unilineage dysplasia
1%
Cerebral haemorrhage
1%
Aplasia pure red cell
1%
Enteritis
1%
Oedema peripheral
1%
Pneumonia cytomegaloviral
1%
Pseudomonal bacteraemia
1%
Spinal fracture
1%
Adenocarcinoma gastric
1%
Suicide attempt
1%
Pleural effusion
1%
Embolism arterial
1%
Peritonsillitis
1%
Proctalgia
1%
Upper gastrointestinal haemorrhage
1%
Cholelithiasis
1%
Bacteraemia
1%
Bronchopulmonary aspergillosis
1%
Clostridium difficile colitis
1%
Device related infection
1%
Gastroenteritis viral
1%
Sinusitis fungal
1%
Urinary tract infection
1%
Post procedural haematoma
1%
Decreased appetite
1%
Transient ischaemic attack
1%
Angioedema
1%
Hypersensitivity vasculitis
1%
Deep vein thrombosis
1%
Haematoma
1%
Enterobacter infection
1%
Gastroenteritis Escherichia coli
1%
Pyoderma gangrenosum
1%
Parainfluenzae virus infection
1%
Acute coronary syndrome
1%
Small intestinal obstruction
1%
Colonic abscess
1%
Oral candidiasis
1%
Septic shock
1%
Limb injury
1%
Soft tissue necrosis
1%
Pulmonary embolism
100%
80%
60%
40%
20%
0%
Study treatment Arm
MDS or CMML: ASTX727
AML: IV Decitabine
MDS or CMML: Not Treated
AML: Not Treated
AML: ASTX727
MDS or CMML: IV Decitabine

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Substudy Arm B: ASTX727 With Low-Calorie/Low-Fat Breakfast Meal on Day 4Experimental Treatment1 Intervention
Participants received ASTX727 once daily on Days 1 through 5 in a 28-day cycle (Cycle 1). Participants fasted for at least 2 hours before and 2 hours after dosing on Days 1, 3, 5 and for at least 10 hours before and 4 hours after dosing on Day 2. Participants received low-calorie/low-fat breakfast meal after an overnight fast of at least 10 hours before dosing on Day 4 and will continue to fast for at least 4 hours post-dose. Participants continued treatment with ASTX727 in Cycle 2 onwards in the ASTX727-06 study at the Investigator's discretion, where they continued to receive ASTX727 unless there was occurrence of disease progression requiring alternative therapy, unacceptable toxicity, noncompliance, a decision to discontinue treatment, or if the participant withdraws from the study.
Group II: Substudy Arm A: ASTX727 With High-Calorie/High-Fat Breakfast Meal on Day 4Experimental Treatment1 Intervention
Participants received ASTX727 once daily on Days 1 through 5 in a 28-day cycle (Cycle 1). Participants fasted for at least 2 hours before and 2 hours after dosing on Days 1, 3, 5 and for at least 10 hours before and 4 hours after dosing on Day 2. Participants received a high-calorie/high-fat breakfast meal after an overnight fast of at least 10 hours before dosing on Day 4 and continued to fast for at least 4 hours post-dose. Participants continued treatment with ASTX727 in Cycle 2 onwards in the ASTX727-06 study at the Investigator's discretion, where they continued to receive ASTX727 unless there was occurrence of disease progression requiring alternative therapy, unacceptable toxicity, noncompliance, a decision to discontinue treatment, or if the participant withdraws from the study.
Group III: Main Extension Study: ASTX727Experimental Treatment1 Intervention
The recommended starting dose is the fixed-dose combination (FDC) standard dose (SD) tablet, containing 100 mg cedazuridine and 35 mg decitabine, once daily, Days 1 through 5 in 28-day cycles. Participants should receive ASTX727 at the same dose they received in the last cycle of their parent study; if an adjustment from that dose is required, a different total cycle dose may be employed, as guided by the dose adjustment guidelines in the parent study protocol.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ASTX727
2018
Completed Phase 3
~270

Find a Location

Who is running the clinical trial?

Taiho Oncology, Inc.Lead Sponsor
78 Previous Clinical Trials
12,758 Total Patients Enrolled
Astex Pharmaceuticals, Inc.Lead Sponsor
95 Previous Clinical Trials
7,221 Total Patients Enrolled
Yuri SanoStudy DirectorAstex Pharmaceuticals, Inc.

Media Library

ASTX727 (Nucleoside Analog) Clinical Trial Eligibility Overview. Trial Name: NCT04093570 — Phase 2
Chronic Myelomonocytic Leukemia Research Study Groups: Substudy Arm A: ASTX727 With High-Calorie/High-Fat Breakfast Meal on Day 4, Substudy Arm B: ASTX727 With Low-Calorie/Low-Fat Breakfast Meal on Day 4, Main Extension Study: ASTX727
Chronic Myelomonocytic Leukemia Clinical Trial 2023: ASTX727 Highlights & Side Effects. Trial Name: NCT04093570 — Phase 2
ASTX727 (Nucleoside Analog) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04093570 — Phase 2
Chronic Myelomonocytic Leukemia Patient Testimony for trial: Trial Name: NCT04093570 — Phase 2
~10 spots leftby Jan 2025